Bio-Rad Laboratories has launched a portfolio of Vericheck ddPCR kits designed to support quality control workflows in cell and gene therapy manufacturing and other biopharmaceutical applications.

The kits are compatible with the company’s QX700 digital droplet PCR (ddPCR) platform and are intended to simplify quality control testing during advanced therapeutic development and manufacturing.

The new portfolio includes assays for mycoplasma detection, empty and full viral capsid analysis, replication-competent lentivirus testing, Chinese hamster ovary (CHO) residual DNA quantification and Escherichia coli residual DNA quantification.

According to Bio-Rad, the kits provide validated workflows for critical quality control processes including contamination detection, vector characterisation and residual host cell DNA testing, supporting developers working in advanced therapies.

The company said the QX700 platform enables seven-colour multiplexing and can process up to 384 reactions in approximately two and a half hours, while requiring minimal sample input and supporting continuous loading to improve laboratory throughput.

Stephen Kulisch, vice president of marketing, digital biology group at Bio-Rad Laboratories, said: “The expansion of our range of Vericheck ddPCR Kits offers validated workflows with unmatched precision and sensitivity, combined with the power of the QX700 platform, enabling scalable, streamlined workflows and faster time to actionable results.”

Quality control testing plays a critical role in the manufacture of advanced therapies by confirming product identity, monitoring contamination and supporting regulatory compliance throughout development and production.

Bio-Rad said the Vericheck portfolio has been developed to provide ready-to-use assays for common quality control requirements in biopharmaceutical manufacturing, helping developers standardise testing while improving confidence in product safety and quality.